apalutamide will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.
benzhydrocodone/acetaminophen, metaxalone.Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.benzhydrocodone/acetaminophen and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
buprenorphine subdermal implant and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
buprenorphine transdermal and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
buprenorphine, long-acting injection and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
metaxalone, calcium/magnesium/potassium/sodium oxybates.Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
fentanyl and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
fentanyl intranasal and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
fentanyl iontophoretic transdermal system and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
fentanyl transdermal and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
fentanyl transmucosal and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
fexinidazole will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.
hydrocodone, metaxalone.Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
idelalisib will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates
ivosidenib will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
lopinavir will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
methohexital and metaxalone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
metaxalone, metoclopramide intranasal.Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
metaxalone and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychom*otor performance and cause daytime impairment.
metaxalone, sodium oxybate.Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
sufentanil SL, metaxalone.Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
tucatinib will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.
voxelotor will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.
metaxalone, zuranolone.Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of zuranolone with other CNS depressants may increase impairment of psychom*otor performance or CNS depressant effects. If unavoidable, consider dose reduction. .
abiraterone increases levels of metaxalone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.
metaxalone increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may potentiate botulinum toxin effects, which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects.
acrivastine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and alfentanil both increase sedation. Use Caution/Monitor.
alprazolam and metaxalone both increase sedation. Use Caution/Monitor.
amisulpride and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and amitriptyline both increase sedation. Use Caution/Monitor.
amobarbital and metaxalone both increase sedation. Use Caution/Monitor.amobarbital will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
metaxalone and amoxapine both increase sedation. Use Caution/Monitor.
metaxalone increases and amphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
metaxalone and apomorphine both increase sedation. Use Caution/Monitor.
metaxalone and aripiprazole both increase sedation. Use Caution/Monitor.
asenapine and metaxalone both increase sedation. Use Caution/Monitor.
asenapine transdermal and metaxalone both increase sedation. Use Caution/Monitor.
avapritinib and metaxalone both increase sedation. Use Caution/Monitor.
azelastine and metaxalone both increase sedation. Use Caution/Monitor.
baclofen and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and belladonna and opium both increase sedation. Use Caution/Monitor.
metaxalone and benperidol both increase sedation. Use Caution/Monitor.
metaxalone increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
brexanolone, metaxalone.Either increases toxicity of the other by sedation. Use Caution/Monitor.
brexpiprazole and metaxalone both increase sedation. Use Caution/Monitor.
brimonidine and metaxalone both increase sedation. Use Caution/Monitor.
brivaracetam and metaxalone both increase sedation. Use Caution/Monitor.
brompheniramine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and buprenorphine both increase sedation. Use Caution/Monitor.
metaxalone and buprenorphine buccal both increase sedation. Use Caution/Monitor.
buprenorphine, long-acting injection increases effects of metaxalone by Other (see comment). Modify Therapy/Monitor Closely. Comment: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and increase risk for respiratory depression. Monitor for signs of respiratory depression that may be greater than otherwise expected and decrease muscle relaxant dosage as necessary.
butabarbital and metaxalone both increase sedation. Use Caution/Monitor.
butalbital and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and butorphanol both increase sedation. Use Caution/Monitor.
cannabidiol, metaxalone. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition with the coadministration of CYP1A2 substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate.
carbinoxamine and metaxalone both increase sedation. Use Caution/Monitor.
cariprazine and metaxalone both increase sedation. Use Caution/Monitor.
carisoprodol and metaxalone both increase sedation. Use Caution/Monitor.
cenobamate will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.
chloral hydrate and metaxalone both increase sedation. Use Caution/Monitor.
chlordiazepoxide and metaxalone both increase sedation. Use Caution/Monitor.
chlorpheniramine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and chlorpromazine both increase sedation. Use Caution/Monitor.
chlorzoxazone and metaxalone both increase sedation. Use Caution/Monitor.
cinnarizine and metaxalone both increase sedation. Use Caution/Monitor.
clemastine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
metaxalone and clomipramine both increase sedation. Use Caution/Monitor.
clonazepam and metaxalone both increase sedation. Use Caution/Monitor.
clorazepate and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and clozapine both increase sedation. Use Caution/Monitor.
metaxalone and codeine both increase sedation. Use Caution/Monitor.
crofelemer increases levels of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.
cyclizine and metaxalone both increase sedation. Use Caution/Monitor.
cyclobenzaprine and metaxalone both increase sedation. Use Caution/Monitor.
cyproheptadine and metaxalone both increase sedation. Use Caution/Monitor.
dabrafenib will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
dantrolene and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychom*otor performance and cause daytime impairment.
metaxalone increases effects of daxibotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may potentiate botulinum toxin effects, which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects.
metaxalone and desipramine both increase sedation. Use Caution/Monitor.
desloratadine and metaxalone both increase sedation. Use Caution/Monitor.
dexchlorpheniramine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
dexmedetomidine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and dextromoramide both increase sedation. Use Caution/Monitor.
metaxalone and diamorphine both increase sedation. Use Caution/Monitor.
diazepam and metaxalone both increase sedation. Use Caution/Monitor.
diazepam buccal and metaxalone both increase sedation. Use Caution/Monitor.diazepam buccal, metaxalone.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
diazepam intranasal, metaxalone.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.diazepam intranasal and metaxalone both increase sedation. Use Caution/Monitor.
difelikefalin and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and difenoxin hcl both increase sedation. Use Caution/Monitor.
dimenhydrinate and metaxalone both increase sedation. Use Caution/Monitor.
diphenhydramine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
metaxalone and dipipanone both increase sedation. Use Caution/Monitor.
metaxalone increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
metaxalone and dosulepin both increase sedation. Use Caution/Monitor.
metaxalone and doxepin both increase sedation. Use Caution/Monitor.
doxylamine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and droperidol both increase sedation. Use Caution/Monitor.
efavirenz will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
elagolix decreases levels of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of metaxalone by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.
encorafenib, metaxalone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.
esketamine intranasal, metaxalone.Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
estazolam and metaxalone both increase sedation. Use Caution/Monitor.
eszopiclone and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and ethanol both increase sedation. Use Caution/Monitor.
etomidate and metaxalone both increase sedation. Use Caution/Monitor.
fedratinib will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.
metaxalone increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
metaxalone and fluphenazine both increase sedation. Use Caution/Monitor.
flurazepam and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and ganaxolone both increase sedation. Use Caution/Monitor.
metaxalone and haloperidol both increase sedation. Use Caution/Monitor.
metaxalone and hydromorphone both increase sedation. Use Caution/Monitor.
hydroxyzine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and iloperidone both increase sedation. Use Caution/Monitor.iloperidone increases levels of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.
metaxalone and imipramine both increase sedation. Use Caution/Monitor.
metaxalone increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may potentiate botulinum toxin effects, which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects.
istradefylline will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
ketamine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
lasmiditan, metaxalone.Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
lemborexant, metaxalone.Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
lenacapavir will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
metaxalone increases effects of letibotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may potentiate botulinum toxin effects, which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects.
levetiracetam and metaxalone both increase sedation. Use Caution/Monitor.
levocetirizine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and levorphanol both increase sedation. Use Caution/Monitor.
metaxalone and lofepramine both increase sedation. Use Caution/Monitor.
metaxalone and lofexidine both increase sedation. Use Caution/Monitor.
loprazolam and metaxalone both increase sedation. Use Caution/Monitor.
loratadine and metaxalone both increase sedation. Use Caution/Monitor.
lorazepam and metaxalone both increase sedation. Use Caution/Monitor.
lorcaserin will increase the level or effect of metaxalone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
lormetazepam and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and loxapine both increase sedation. Use Caution/Monitor.
metaxalone and loxapine inhaled both increase sedation. Use Caution/Monitor.
lumateperone and metaxalone both increase sedation. Use Caution/Monitor.
lurasidone, metaxalone.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.lurasidone and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and maprotiline both increase sedation. Use Caution/Monitor.
metaxalone and marijuana both increase sedation. Use Caution/Monitor.
meclizine and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and melatonin both increase sedation. Use Caution/Monitor.
metaxalone and meperidine both increase sedation. Use Caution/Monitor.
metaxalone and meprobamate both increase sedation. Use Caution/Monitor.
metaxalone and methadone both increase sedation. Use Caution/Monitor.
metaxalone and methocarbamol both increase sedation. Use Caution/Monitor.
methsuximide and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
midazolam and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
mifepristone will increase the level or effect of metaxalone by Other (see comment). Use Caution/Monitor. Inhibits CYP2C8/2C9; use smallest recommended doses for substrates and monitor
mirabegron will increase the level or effect of metaxalone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
metaxalone and mirtazapine both increase sedation. Use Caution/Monitor.
mitotane decreases levels of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.
metaxalone and morphine both increase sedation. Use Caution/Monitor.
metaxalone and motherwort both increase sedation. Use Caution/Monitor.
metaxalone and moxonidine both increase sedation. Use Caution/Monitor.
metaxalone and nabilone both increase sedation. Use Caution/Monitor.
metaxalone and nalbuphine both increase sedation. Use Caution/Monitor.
nefazodone will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
metaxalone and nortriptyline both increase sedation. Use Caution/Monitor.
metaxalone and olanzapine both increase sedation. Use Caution/Monitor.
oliceridine, metaxalone.Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.metaxalone increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.
metaxalone increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may potentiate botulinum toxin effects, which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects.
metaxalone and opium tincture both increase sedation. Use Caution/Monitor.
metaxalone and orphenadrine both increase sedation. Use Caution/Monitor.
oxazepam and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and oxycodone both increase sedation. Use Caution/Monitor.
metaxalone and oxymorphone both increase sedation. Use Caution/Monitor.
metaxalone and paliperidone both increase sedation. Use Caution/Monitor.
metaxalone and papaveretum both increase sedation. Use Caution/Monitor.
metaxalone and papaverine both increase sedation. Use Caution/Monitor.
metaxalone and pentazocine both increase sedation. Use Caution/Monitor.
pentobarbital and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and perphenazine both increase sedation. Use Caution/Monitor.
phenobarbital and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
metaxalone and pholcodine both increase sedation. Use Caution/Monitor.
metaxalone and pimozide both increase sedation. Use Caution/Monitor.
metaxalone increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may potentiate botulinum toxin effects, which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects.
primidone and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and prochlorperazine both increase sedation. Use Caution/Monitor.
promethazine and metaxalone both increase sedation. Use Caution/Monitor.
propofol and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
metaxalone and protriptyline both increase sedation. Use Caution/Monitor.
quazepam and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and quetiapine both increase sedation. Use Caution/Monitor.
metaxalone and ramelteon both increase sedation. Use Caution/Monitor.
metaxalone increases effects of remifentanil by pharmacodynamic synergism. Modify Therapy/Monitor Closely. CNS depressant effect increased.
remimazolam, metaxalone.Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
metaxalone increases effects of rimabotulinumtoxinB by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may potentiate botulinum toxin effects, which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects.
metaxalone and risperidone both increase sedation. Use Caution/Monitor.
rucaparib will increase the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.
metaxalone and scullcap both increase sedation. Use Caution/Monitor.
secobarbital and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and shepherd's purse both increase sedation. Use Caution/Monitor.
stiripentol, metaxalone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.stiripentol, metaxalone.Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
metaxalone and sufentanil both increase sedation. Use Caution/Monitor.
metaxalone and tapentadol both increase sedation. Use Caution/Monitor.
tazemetostat will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
tecovirimat will decrease the level or effect of metaxalone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.
temazepam and metaxalone both increase sedation. Use Caution/Monitor.
teriflunomide increases levels of metaxalone by Other (see comment). Use Caution/Monitor. Comment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates.teriflunomide decreases levels of metaxalone by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.
metaxalone and thioridazine both increase sedation. Use Caution/Monitor.
metaxalone and thiothixene both increase sedation. Use Caution/Monitor.
metaxalone and topiramate both increase sedation. Modify Therapy/Monitor Closely.
metaxalone and tramadol both increase sedation. Use Caution/Monitor.
metaxalone and trazodone both increase sedation. Use Caution/Monitor.
triazolam and metaxalone both increase sedation. Use Caution/Monitor.
triclofos and metaxalone both increase sedation. Use Caution/Monitor.
metaxalone and trifluoperazine both increase sedation. Use Caution/Monitor.
metaxalone and trimipramine both increase sedation. Use Caution/Monitor.
metaxalone increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
metaxalone and ziconotide both increase sedation. Use Caution/Monitor.
metaxalone and ziprasidone both increase sedation. Use Caution/Monitor.
metaxalone and zotepine both increase sedation. Use Caution/Monitor.
